Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection


Posted in: Drug Trial News | Disease/Infection News

Tags: Antibodies, Antigen, Cell, Cholesterol, Cirrhosis, Clinical Trial, DNA, Drug Delivery, Drugs, Genes, Hepatitis B, Hospital, Obesity, Oncology, Placebo, RNA, RNAi Therapeutics, siRNA, Virus